Delhi, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Global Natural Killer (NK) Cell Therapeutics Market Trends, Companies & Clinical Trials Insight 2023 Report Highlights:
- Global Natural Killer (NK) Cell Therapeutics Market Trends Insight
- Partnerships & Funding for Natural Killer Cell Therapies : > 10 Recent Deals
- Global Natural Killer Cell Therapies Clinical Trials Insight: > 200 Therapies
- Global Natural Killer Cell Therapies Clinical Trials By Company, Indication & Phase
- Proprietary Technologies By Company Insight: > 10 Technologies
- FDA Fast Track & Orphan Designation insight
- Detailed Outlook On More than 30 Companies
Download Report:
This decade has witness the booming success of immunotherapy and there is no better time to launch new models that can serve the field of immunotherapy. As this treatment modality revolutionized the treatment landscape of cancer, it has become a mainstream therapeutic approach. Growth in this field has pushed forwards the introduction of novel targets and therapies from labs to clinical trials. One such approach is NK cell therapy which has been showing its therapeutic potential in research studies as well as clinical trials.
The emergence of cell therapy has being one of the main reasons as to why such success has been witnessed in the field of immunotherapy. While there have been different forms of cell therapies introduced in the market, they all have targeted a certain patient population, maintain their identity in the market. Welcoming adoption towards cell therapy has allowed the introduction of NK cell based approach which is being extensively tested in pre-clinical studies as well as clinical trials.
While clinical success has been witnessed in hematological malignancies, little progress is perceived in the case of solid tumors. Having a distinct advantage over other adoptive cell therapies, the utilization of NK cells has the potential to cause a significant impact on the current existing segment of cancer cell therapy. Syena, a new oncology focused product company pioneering T cell receptor NK cell therapies. The company launched and built on the intellectual property and technology from MD Anderson Cancer centre and Replay, a genome writing company will aim to create the next generation of cell therapy.
Syena is said to build a clinical pipeline of engineered cell therapies using its novel TCR-NK cell platform which is licensed exclusively from MD Anderson. This therapy platform will combine the advantages of engineered T-cell receptor (TCR) cancer therapy with NK cells which might offer the possibility of improved safety and efficacy through multi-armed approach incorporating natural and artificial mechanisms.
The healthcare system stands on three main therapeutic pillars; infrastructure, appropriate regulations and widespread clinical adoption. Comparing to the success of present adoptive cell therapies and their prevalent adoption, suggests a similar future outlook for NK cell therapies. Up until now, cell therapies have seen major progress in cancer treatment however; they seem to have a limitation in the case of solid tumors. With NK cells offering an approach with improved results, remarkable advancements have been made to grasp the function of NK cells as an effective cancer immunotherapy tool.
With no therapeutic approach approved in the case of NK cell therapies, the global market remains at a nascent stage. Several pharmaceutical companies have been aiming to launch their novel NK cell therapy which will act as a next generation of anti-cancer therapeutics for the treatment of several cancer indications as well as infectious diseases. Some of the key frontrunners in this market segment include; Affimed NV, GC Cell, Takeda Pharmaceuticals, Glycostem Therapeutics and others.
Being a unique approach compared to the existing cell therapies, the first approved therapy can be considered to dominate the market segment for a prolonged period of time. The first approval might also push forward other candidates in clinical trials but for now, it can only be anticipated how the market will shift upon the commercial availability of first NK cell based therapy. If compared to the success of Kymriah, the first approved cell therapy; this therapeutic approach can be predicted to have the same or even advanced sales given the fact that NK cell therapy is aimed to be a cost-effective form of current cell therapies.
With Kymriah still engaged in encouraging sales, the introduction of NK cell therapy is said to change the treatment landscape of not only cancer but other disorders as well. It is only a matter of time when this approach enters the commercial market but the first approved therapy will certainly have an upper edge. Additionally, with companies also investigating the combinational use of NK cell therapy further expands its reach making it easier for this therapy to penetrate the market.
This report aims to provide an in depth analysis about the therapies currently under clinical trials and the progress they have made so far. Also highlighting the most anticipated NK cell therapy in the market, the report aims to give a forecast on the initial sales of the therapeutic approach and how it will shift and open further opportunities in the market segment. Furthermore, our report also sheds information on current company strategies being initiated so as to develop a certain threshold in this new and untouched NK cell therapy market.
